Biological or Mechanical Prostheses in Tricuspid Position? A Meta-Analysis of Intra-institutional Results
|
|
- Melina Lane
- 5 years ago
- Views:
Transcription
1 Biological or Mechanical Prostheses in Tricuspid Position? A Meta-Analysis of Intra-institutional Results CARDIOVASCULAR Giulio Rizzoli, MD, FETCS, Igor Vendramin, MD, Georgios Nesseris, MD, Tomaso Bottio, MD, Cosimo Guglielmi, MD, and Laura Schiavon, DStat Istituto di Chirurgia Cardiovascolare and Centro Informativo di Ateneo, Università di Padova, Padova, Italy Background. Tricuspid valve replacement (TVR) is an uncommon procedure. The use of biological vs mechanical prostheses in TVR has pros and cons. Therefore, we debate the choice between the different types of valves by means of a meta-analysis of studies of the last decade. Methods. The heading tricuspid valve replacement and (bio* or mec*) was used to retrieve studies from Medline, Current Contents, and Embase. Eight out of 11 studies met the preset strict criteria: intra-institutional comparison of results of biological or mechanical TVR. Survival of hospital-discharged patients was recalculated to reduce the effect of unbalanced perioperative risk factors on overall survival. Hazard ratio was obtained from actuarial survival graphics comparison and at-risk groups, according to the method described by Parmar. If missing, the number of patients at risk was approximated assuming constant and noninformative censoring. Hazard pooling was done according to study heterogeneity. Bioprostheses were assumed as the gold standard and mechanical prostheses assumed as the challenging device. Therefore, a hazard more than 1 pointed to a higher risk of mechanical prostheses. Our 1998 study was updated for this analysis. Results. In this study, 1,160 prostheses and 6,046 follow-up years were analyzed. The pooled survival hazard ratio of mechanical prostheses versus bioprostheses was 1.07 (0.84 to 1.35, p 0.60). The pooled freedom from reoperation hazard ratio was 1.24 (0.67 to 2.31, p 0.67). Pooled survival differences were trivial, favoring mechanical prostheses at 1 ( 0.04%) and 15 years ( 1.1%) and favoring bioprostheses ( 1.8%) at 10 years. Conclusions. There is not a gold standard in tricuspid prostheses replacement. Prosthetic choice is left to the surgeon s clinical judgment, taking into consideration each patient s characteristics and needs. (Ann Thorac Surg 2004;77: ) 2004 by The Society of Thoracic Surgeons Tricuspid valve replacement (TVR) is a r?ther uncommon operation. Most institutional series involve small numbers of cases and a large variety of prosthetic models. Furthermore, tricuspid prostheses are frequently combined with left heart valve prostheses, either on the same operation or on reoperation. These circumstances, along with the institutional differences and the risk factors of the individual patient, including sex, age, and clinical status, make identification of the most suitable prosthesis difficult [1 3]. Does this multifaceted target and heterogeneity prevent conclusions? We try to gain a better insight from a meta-analysis of the literature results comparing biological and mechanical prostheses within the same institution. Material and Methods Accepted for publication Oct 2, Address reprint requests to Dr Rizzoli, Cardiochirurgia, Via Giustiniani 2, Padova, Italy; giulio.rizzoli@unipd.it. The literature published in the last 10 years, available online through the Medline, Current Contents, and Embase, using the key words tricuspid valve replacement and (Bio* or Mec*), was reviewed. The guidelines and techniques for research synthesis of observational studies [4] were applied and our published data [5] were reviewed, excluding very old prosthetic models applied before Meta-analysis of results obtained with the surgical use of biological or mechanical tricuspid valve prostheses was organized in steps as previously detailed [6]. The main end point was the late survival of patients after operation. Survival rate of patients discharged from hospital was analyzed considering that it was less influenced by operative and patient specific risk factors than overall survival. This required recalculating the survival rates after exclusion of early mortality. Other minor points were freedom from reoperation and survival without reoperation. Statistics The most appropriate effect index, to evaluate time related effects of surgical procedures, was the hazard ratio and its confidence limits. The extraction of this index was performed according to the techniques suggested by Parmar [7]. We assumed biological prostheses as the gold 2004 by The Society of Thoracic Surgeons /04/$30.00 Published by Elsevier Inc doi: /j.athoracsur
2 CARDIOVASCULAR 1608 RIZZOLI ET AL Ann Thorac Surg BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION 2004;77: Table 1. Selected Studies of the Literature Study (Publication Date) Location Operative era No. Bio-All-Mec M/F ratio Age (Years) Bio-All-Mec Operative Death(%) Van Nooten (1995) [11] Belgium Scully (1995) [20] Canada Munro (1995) [18] Canada Farinas (1996) [19] France Hayashi (1996) [16] Japan Ratnatunga (1998) [14] UK Dalrymple (1999) [17] UK Do (2000) [12] France Kaplan (2002) [15] Turkey Carrier (2003) [3] Canada Local data (2003) Italy Total (mean) (0.37) (49.3) (19.2) Bio biological; Mec mechanical; M/F male/female. standard and mechanical prostheses as the challenging device. Therefore, a hazard ratio less than 1 indicates better results of mechanical prostheses because of larger reduction of late mortality and a hazard ratio greater than 1 indicates a higher risk of mechanical prostheses. Hazard ratio pooling was done according to the heterogeneity test [6]. The STATA package (Stata Corp., College Station, TX) was used in the analysis [8]. Survival probability with mechanical or biological prostheses was averaged and compared at 1, 5, 10, and 15 years and survival differences were reported with their confidence limits. An attempt to explain the hazard ratio variability among the studies was made utilizing the Poisson regression or negative binomial maximumlikelihood regression [9] of the independent variables summarized in Tables 1, 2, and 3. The hazard ratio was the dependent variable and the total follow-up time was the weighting exposure variable. Results Results of the Cardiac Surgery in Our Institution Between January 1, 1970 and December 31, 2002, 101 tricuspid prostheses (71 porcine, 7 pericardial, 15 tilting disk, and 8 bileaflet) were implanted on 84 patients. The median follow-up time was 7.3 years (6.9 biological, 7.3 mechanical) and total follow-up time was 646 years (511 biological, 135 mechanical). Late survival, freedom from reoperation, and survival without reoperation at 1, 5, 10, and 15 years are summarized in the Appendix. Age corrected estimates of the hazard ratio of survival (0.84, 0.36 to 1.93, p 0.67), of freedom from reoperation (0.86, 0.25 to 3.04, p 0.72), and of survival without reoperation (0.84, 0.42 to 1.69, p 0.82) were used for comparison with literature studies. Ninety-seven percent of the biological, and all the mechanical, prostheses are receiving anticoagulant treatment. Table 2. Follow-Up and Survival Data Study Mean Follow-up (Years) Total Follow-up (Years) Mec total follow-up (Years) Bio total Follow-up (Years) Biological Valve 5 yr-surv. Mechanical Valve 5 yr-surv. Van Nooten [11] a 70 a Scully [20] Munro [18] Farinas [19] Hayashi [16] a 71 a Ratnatunga [14] Dalrymple [17] Do [12] Kaplan [15] Carrier [3] Local data Total (mean) (6.8) (66.7) (66.4) a survival of hospital discharged patients. Bio biological; Mec mechanical; 5 yr-surv. overall 5 year postoperative survival.
3 Ann Thorac Surg RIZZOLI ET AL 2004;77: BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION Table 3. Risk Factors and Complication Incidence NYHA 3 4 ratio Bio-all-Mec Reoperation Ratio Urgent Ratio Bio-all-Mec Single Valve Ratio Bio-all-Mec Triple Valve Ratio Bio-all-Mec Thromb. Incidence % pt/years 1609 SVD Incidence % pt/years CARDIOVASCULAR Van Nooten [11] Scully [20] Munro [18] Farinas [19] Hayashi [16] Ratnatunga [14] Dalrymple [17] Do [12] Kaplan [15] Carrier [3] Local data Total (mean) (0.81) (0.53) (0.19) (0.36) (0.26) Bio biological; Mec mechanical; SVD structural valve deterioration; Thromb. thrombosis. Meta-Analysis According to our research of the literature, 12 studies reported an intrainstitutional comparison of the biological versus mechanical prostheses. The studies of Van Nooten and colleagues [10, 11] and of Do and colleagues [12, 13] were replicated on two different journals, with the intent that the duplicated data were excluded from metaanalysis, to avoid estimation bias. One registry-based study [14], although not strictly intrainstitutional, was included for its surgical relevance. Therefore a total of 11 studies, with 646 mechanical and 514 biological tricuspid prostheses, were further analyzed. They were summarized in Tables 1, 2, and 3 according to time of publication, geographical location of the study, operative time limits, number of prostheses, demographic factors, and perioperative deaths. Demographic Factors Mean age was 49.3 years and the median age was 50 years (interquartile range 46 to 55) (Table 1). It ranged from very young patient cohorts (36 years in the Turkish study [15] and 40 years in the Japanese study [16]) to much older cohorts (59 years in the UK study [17]). Four studies [3, 5, 15, 18] included separate mean ages for mechanical and biological tricuspid prostheses. Males were 36% (range, 2.6% to 80%). Mean male to female ratio was 0.37, median ratio 0.58 (interquartile range, 0.27 to 0.46); the studies of Munro and colleagues [18] and Dalrymple and colleagues [17] have very high female prevalence. Follow-Up The total follow-up summed 6,046 years (Table 2). Mean duration was 6.8 years, median 6.5 (interquartile range, 5.6 to 7.8 years): the studies of Munro and colleagues [18] and Carrier and colleagues [3] have the shortest follow-up (3.7 to 4.0), while those of Farinas and colleagues [19] and Dalrymple and colleagues [17] have the longest (9.5 to 8.1). Total follow-up of biological and mechanical prostheses was calculated assuming a follow-up split proportional to the prosthetic prevalence. In two recent studies [3, 15] total follow-up and follow-up of the mechanical or the biological prostheses was calculated from the number of patients at risk at the stated time, as suggested in CTSNET Surgeon s Forum: Dilemmas in Adult Cardiac Surgery [1]. Risk Factors Risk factors are summarized in Table 3 for each study as prevalence ratios: New York Heart Association (NYHA) class 3 to 4; previous operation; urgent operation; isolated tricuspid valve replacement; and triple valve replacement. By Poisson regression analysis, none of these variables was significant to explain the hazard ratio variability among studies with the exception of the male-to-female ratio (p 0.055). In fact, hazard ratio was in studies with a lower male proportion ( 46%) and in patients with a higher male prevalence. Complications THROMBOSIS. There was a large variability of this complication among the series with a median of 1.28% pt/year episodes (interquartile range, 0.50% to 2.22% pt/year) (Table 3). The series of Ratnatunga and colleagues [14] and Farinas and colleagues [19] report the lowest estimate; Do and colleagues [12] and Carrier and colleagues [3] report the highest. Van Nooten and colleagues [11] and our series observed one case of biological valve thrombosis. Anticoagulant treatment of biological valves was lifelong in the series of Scully and Armstrong [20]; it was limited to three months in the series of Van Nooten and colleagues [11], Hayashi and colleagues [16], Kaplan and colleagues [15], and our series, and was missing in the other papers. STRUCTURAL VALVE DETERIORATION. The median valve period was 1.71% pt/year (interquartile range, 0.42% to 2.27% pt/year). The series of Ratnatunga and colleagues [14],
4 CARDIOVASCULAR 1610 RIZZOLI ET AL Ann Thorac Surg BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION 2004;77: Table 4. Hazard Ratio of Mechanical Versus Biological Prostheses At Risk Biological At Risk Mechanical HR UCL p value Survival Ratnatunga [14] Scully [20] Van Nooten [11] Hayashi [16] Kaplan [15] Dalrymple [17] Carrier a [3] Local data a Overall Reoperation freedom Munro [18] Carrier a [3] infinite Kaplan [15] Dalrymple [17] Local data a Overall Reoperation free survival Van Nooten [11] Local study a Overall a age corrected values. HR hazard ratio; low confidence limits; UCL upper confidence limits. Farinas and colleagues [19], and Munro and colleagues [18] had the lowest incidence; Do and colleagues [12] and Carrier and colleagues [3] reported the highest. Overall, 21 mechanical valve thromboses and 37 deterioration episodes were reported. The incidence rate of thrombosis was 0.87% pt/year and the incidence of the deterioration was 1.02% pt/year. The difference was not significant (p 0.25). Hazard Ratio Seven studies [3, 12, 14 17, 20], plus our series, made possible the computation of the survival hazard ratio (Table 4). Two of these studies [17, 20] did not report the at-risk group at the stated follow-up times and this figure was generated according to Parmar [7]. A third study [16] compared survival, excluding three late deaths due to suicide, sepsis, and pneumonia. The study was utilized because our interest was on survival rate comparison and not on absolute survival values. The pooled hazard ratio estimate was 1.07 (0.84 to 1.35, p 0.60) (Fig 1). Four papers [3, 15, 17, 18] and ours presented data on the freedom from reoperation (Table 4) Among these studies, Carrier and colleagues [3] compared prostheses for a follow-up of five years, while the study of Munro and colleagues [18] had a very small number of mechanical prostheses followed beyond two years. In both series it was impossible to obtain a reasonable estimate of the variance and confidence limits. In the three remaining studies the pooled hazard ratio estimate was 1.24 (0.67 to 2.31, p 0.50) (Fig 2). A single study [11] plus ours enabled the comparison of the survival without reoperation (Table 4), with both having similar results. The pooled estimate was 0.86 (0.70 to 1.05, p 0.14). The survival of the biological and mechanical prostheses was available for 7 series [3, 12, 14, 15 17, 20] plus ours (Fig 3). Among 391 patients discharged with mechanical prostheses, the pooled 1, 5, 10, and 15 year survival of the hospital-discharged patients was 86.9%, 73.5%, 60.2%, and 47.8%, respectively; among 477 patients discharged Fig 1. Survival hazard ratio of each study with related confidence limits. The pooled hazard ratio is indicated from the dotted line.
5 Ann Thorac Surg RIZZOLI ET AL 2004;77: BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION Fig 2. Reoperation free hazard ratio of each study with related confidence limits. The pooled hazard ratio is indicated from the dotted line. (HR hazard ratio.) with tricuspid bioprostheses, survival was 86.5%, 73.6%, 62%, and 46.7%, respectively. Five-year survival was identical. Differences were trivial and favoring mechanical prostheses at 1 year ( 0.04, ) and at 15 years ( 1.1, 24 26), favoring biological prostheses at 10 years (1.8, 16 12). Comment Tricuspid valve replacement was performed for the first time in Fortunately, this operation is rarely required and it is performed in less than 2% of all valve operations [6]. Therefore, most institutional series involve a small number of patients so this makes difficult any statistical evaluation of the performance of the prostheses. Therefore, as randomized studies are not possible in this setting, observational studies are the only available source of information. This limitation increases the confounding due to intrinsic patient factors, to extrinsic operative variability, and to data reporting. Biological prostheses were initially considered ideal in Fig 3. Average survival of the hospital-discharged patients, at stated follow-up years, from the studies of Table 1. The difference in survival between biological and mechanical prostheses is reported with the confidence limits the tricuspid position because they would not require anticoagulation and were expected to have a slower degeneration than in the mitral or aortic position. However, this belief was contradicted by the finding of pannus formation on the mural cusp [21, 22] and by limited durability of about 7 to 9 years [3 5]. On the other hand, the new bileaflet mechanical valves have an appealing low gradient, decreased turbulence, and optimal durability [15]. From neither our previous experience in 1998 [5], nor from the review of the literature, was a clear superiority of biological over mechanical prostheses observed, suggesting that mechanical prostheses should be preferred in young patients and in patients with left sided mechanical prostheses. Two papers have recently reopened the discussion, one suggesting superior results with the use of mechanical devices [15] and the other with the use of biological devices [3]. In commenting on the paper by Kaplan and colleagues [15], we anticipated that a meta-analysis approach, based on the collection of data from the literature comparing the results within the same institution [1], should help to clarify the discordance. It has been written that meta-analysis of nonrandomized studies presents methodologic limits and the results are not reliable [23]. However, we share the opinion that some numerical information is better than none. Therefore, we utilized the methodologic adjustments proposed by the meta-analysis of observational studies in epidemiology (MOOSE) group [4]. We limited our review of the literature to the most recent years and have reanalyzed our results to limit confusion from the most outdated prosthetic models. With the same purpose, we selected only papers comparing mechanical and biological devices within the same institution in order to restrict the errors depending upon intrinsic and extrinsic variables. Calculation of the hazard ratio was selected because it is the most appropriate index to compare late results of different techniques [7], independent of the rate of success. The ratio was obtained by comparing survival rates of hospitaldischarged patients, because it is less influenced by operative and patient specific risk factors than overall survival. Intrainstitutional comparison has the further advantage of ensuring the same accuracy in the collection of the survival data. Similar accuracy in the follow-up is important mainly in recollection to the most common complications: Thrombosis occurs at random but it is most probable in the early postoperative periods because of difficulties in rapidly reaching a good anticoagulation control. Conversely, degeneration of biological prostheses requires time to develop so that its real occurrence depends on follow-up time. The median incidence of mechanical valve thrombosis in this composite series, with a rather large mixture of mechanical valves, was 1.28% pt-years: this rate is intermediate between the initial reports with mono-leaflet valves [24] and the more recent reports with the use of the St. Jude valve (St. Jude Medical, Inc, St. Paul, MN) [25]. CARDIOVASCULAR
6 CARDIOVASCULAR 1612 RIZZOLI ET AL Ann Thorac Surg BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION 2004;77: Analysis of freedom from reoperation indicated a larger hazard of the mechanical prosthesis. This is surprising, because the mean incidence of reoperation due to degeneration of the bioprosthesis is similar to the incidence of reoperation due to thrombosis of mechanical prostheses. This effect was strongly influenced by the study of Kaplan and colleagues [15], which reports 5 mechanical valves and 2 biological events within a short 5 year follow-up. Nonetheless, this group has the most favorable survival with the use of mechanical prostheses and these data support their use, due to their favorable hemodynamic characteristics and durability. In their experience, only 3 thromboses required reoperation. In fact, bileaflet valve thrombosis is rarely fatal and most often is successfully treated by increased anticoagulation or thrombolysis [26]. Conversely, Carrier and colleagues [3] advocate the use of biological prostheses in young patients because of limited life expectancy, unrelated to the type of tricuspid prostheses at long term follow-up. In our review, the pooled late survival of hospital-discharged patients was 60% at 10 years and 50% at 15 years so that many patients are exposed to the risk of valve deterioration. The same authors observed that six patients with first generation bioprostheses were reoperated within 9 years, but they mentioned the event as rare (5%) with the use of the Carpentier-Edwards pericardial prosthesis (Edwards Lifesciences, Irvine, CA). We may argue that the increased durability of second-generation porcine and pericardial prostheses is commonly used to strongly support the use of the biological devices. Comparison of durability of nonconcomitant valve series is, for the moment, suspicious, when unsupported by a propensity score analysis [27]. In our meta-analysis we choose to eliminate the weakest group, with high perioperative mortality, and we recalculated the survival including only the hospitaldischarged patients. We assume that this patients cohort is not affected by a variety of risk factors and is more homogeneous. Despite these restrictions the meta-analysis shows a large heterogeneity among the selected studies, due to several problems. With the exception of the UK Ratnatunga study [14], which is registry-based, the person-time products are small. Some studies did not publish the size of the group at-risk at stated survival times and did not provide a division of the total follow-up according to the use of biological or mechanical devices. Therefore, these data had to be approximated. Confounding of survival estimates due to operative age was not taken into account, with the exception of a single study [3] together with our series. The search of sources of variability of the hazard estimate among studies, with the use of Poisson and negative binomial distribution models, was inconclusive. The single factor identified as source of variability was the proportion shown among sexes and a higher risk of mechanical prostheses in studies with a larger male prevalence (possibly due to sex related etiology and habits). Pooling of the results suggests an identical risk for both prosthetic types. With 249 biological and 186 mechanical valves, followed for 5 years, we have an 85% power to recognize a difference of survival of 10% with a p value of 0.2 (possibly significant). The absence of any difference in the survival data supports the opinion that there is no gold standard for prosthetic tricuspid valve replacement. Nonetheless, results like the meta-analysis presented here have serious limits because they look to the entire forest and not to the single pine. Therefore, we believe that the choice between mechanical or biological prostheses in the tricuspid position should be individualized according to the clinical judgment, the age, the cardiac disease, the etiology, and the habits of the patient, as pointed out by Del Campo and Sherman [2]. It has been stated that the exercise of personal preference by the implanting surgeon in the choice of biological or mechanical prosthesis for tricuspid position seems reasonable [14]. We believe that this statement should be attenuated by several considerations: (1) Tricuspid position makes no exception to the rule that patients more than 65 to 70 years obtain the largest advantage from bioprostheses and younger patients from mechanical prostheses. (2) The extent and the severity of cardiac disease might suggest, in some cases, a limited expectation of life and therefore might favor the use of biological prostheses in younger patients, as concluded by Carrier [3]. On the other hand, concomitant use of left-sided mechanical prostheses favors the same valve for the right heart. (3) The male sex, as opposed to the female sex, is more prone to nonrheumatic etiology, drug addiction, and endocarditis so that it could be favored in the use of biological prostheses. Small size patients with small right ventricles could take advantage of the better hemodynamics of the low profile bileaflet valve as opposed to the largest bioprosthesis, which is prone to develop mural cusp pannus and thrombosis. (4) Finally, by reviewing our data, we found that 97% of living patients with biological tricuspid prostheses are receiving anticoagulant treatment, making the need for anticoagulation a not reliable criterion for the choice of the tricuspid prosthesis. We also found a prosthetic thrombosis in a 16-year-old patient who was not anticoagulated. The occasional report of bioprosthesis thrombosis [11, 29] and pulmonary embolism suggests that anticoagulation treatment should be prolonged indefinitely, even in young patients, unless sinus rhythm [16] and a right atrium less than 5.5 cm [15] exist. This project was supported by MIUR 2003 ROME, Italy, Metaanalysis of the studies comparing long term results of biological and mechanical prostheses. References 1. CTSNET surgeon s forum. Dilemmas in adult cardiac surgery: cfm?catid 8&threadid 4390&highlight_key y&keyword1 tricuspid.
7 Ann Thorac Surg RIZZOLI ET AL 2004;77: BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION 2. Del Campo C, Sherman JR. Tricuspid valve replacement: results comparing mechanical and biological prostheses. Ann Thorac Surg 2000;69: Carrier M, Hebert Y, Pellerin M, et al. Tricuspid valve replacement: an analysis of 25 years of experience at a single center. Ann Thorac Surg 2003;75: Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology. JAMA 2000;283: Rizzoli G, De Perini L, Bottio T, Minutolo G, Thiene G, Casarotto D. Prosthetic replacement of the tricuspid valve: biological or mechanical. Ann Thorac Surg 1998;66:S Rizzoli G, Schiavon L, Bellini P. Does the use of bilateral internal mammary artery (IMA) grafts provide incremental benefit relative to the use of a single IMA graft? A metaanalysis approach. Eur J Cardiothorac Surg 2002;22: Parmar MKB. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med 1998;17: StataCorp Stata Statistical Software. release 7.0 College Station, TX: Stata Corporation. 9. Grunkemeier LG, Wu Y. Our complication rates are lower than theirs: statistical critique of heart valve comparisons. J Thorac Cardiovasc Surg 2003;125: Van Nooten GJ, Caes FL, Francois KJ, et al. The valve choice in tricuspid valve replacement: 25 years of experience. Eur J Cardiothorac Surg 1995;9: Van Nooten G J, Caes F, Taeymans Y, et al. Tricuspid valve replacement: postoperative and long term results. J Thorac Cardiovasc Surg 1995;110: Do QB, Pellerin M, Carrier M, et al. Clinical outcome after isolated tricuspid valve replacement: 20-year experience. Can J Cardiol 2000;16: Do QB, Pellerin M, Carrier M, et al. Remplacement valvulaire tricuspide isole. Resultats a long terme. Arch Mal Coeur Vaiss 2000;93: Ratnatunga CP, Edwards MB, Dore CJ, Taylor KM. Tricuspid valve replacement: UK Heart Valve Registry mid-term results comparing mechanical and biological prostheses. Ann Thorac Surg 1998;66: Kaplan M, Kut MS, Demirtas MM, Cimen S, Ozler A. Prosthetic replacement of tricuspid valve: bioprosthetic or mechanical. Ann Thorac Surg 2002;73: Hayashi J, Saito A, Yamamoto K, Watanabe H, Ohzeki H, 1613 Eguchi S. Is a bioprosthesis preferable in tricuspid valve replacement? Thorac Cardiovasc Surg 1996;44: Dalrymple Hay MJ, Leung Y, Ohri SK, et al. Tricuspid valve replacement: bioprostheses are preferable. J Heart Valve Dis 1999;8: Munro AI, Jamieson WR, Tyers GF, Germann E. Tricuspid valve replacement: porcine bioprostheses and mechanical prostheses. Ann Thorac Surg 1995;60:S Farinas JM, Leclerc Y, Antchouey AM, Mercier LA. Le remplacement valvulaire tricuspidien: suivi clinique et echographique a long terme. Annales de Chirurgie 1996;50: Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg 1995;109: Nakano K, Eishi K, Kosakai Y, et al. Ten year experience with the Carpentier-Edwards pericardial xenograft in the tricuspid position. J Thorac Cardiovasc Surg 1996;111: Guerra F, Bortolotti U, Thiene G, et al. Long-term performance of the Hancock porcine bioprosthesis in the tricuspid position. A review of forty-five patients with fourteen-year follow-up. J Thorac Cardiovasc Surg 1990;99: Shapiro S. Is meta-analysis a valid approach to the evaluation of small effect in observational studies? Am J Epidemiol 1997;50: Thorburn CW, Morgan JJ, Shanahan MX, Chang VP. Longterm results of tricuspid valve replacement and the problem of prosthetic valve thrombosis. Am J Cardiol 1983;51: Nakano K, Koyanagi H, Hashimoto A, Ohtsuka G, Nojiri C. Tricuspid valve replacement with the bileaflet St. Jude medical valve prosthesis. J Thorac Cardiovasc Surg 1994;108: Shapira Y, Sagie A, Jortner R, Adler Y, Hirsch R. Thrombosis of bileaflet tricuspid valve prosthesis: clinical spectrum and the role of non-surgical treatment. Am Heart J 1999;137: Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2000;123: Okada Y, Nasu M, Nishiuchi S, Shomura T. Long-term echocardiographic follow-up of patients with a tricuspid bioprosthesis. ASAIO Trans 1990;36:M (Appendix follows on p. 1614) CARDIOVASCULAR
8 CARDIOVASCULAR 1614 RIZZOLI ET AL Ann Thorac Surg BIOLOGICAL OR MECHANICAL PROSTHESES IN TRICUSPID POSITION 2004;77: Appendix Results of Local Follow-Up Study Freedom From Reoperation (Biological) Year No Reoperated Reoperation Freedom UCL No Reoperated (Mechanical) Reoperation Freedom UCL Survival Without Reoperation (Biological) (Mechanical) Year No. Fail Survival UCL No. Fail Survival UCL Survival (Biological) (Mechanical) Year No. Dead Survival UCL No. Dead Survival UCL Fail dead or reoperated; low confidence limits; UCL upper confidence limits.
Should the tricuspid valve be replaced with a mechanical or biological valve?
doi:10.1510/icvts.2007.159277 Interactive CardioVascular and Thoracic Surgery 6 (2007) 551 557 Best evidence topic - Valves Should the tricuspid valve be replaced with a mechanical or biological valve?
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationMechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation
Mechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation Ho Young Hwang, MD, PhD, Kyung-Hwan Kim, MD, PhD, Ki-Bong Kim, MD, PhD, and Hyuk
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationStandarized definition of bioprosthetic valve deterioration and failure
Translational aortic valve research. From biology to treatment Standarized definition of bioprosthetic valve deterioration and failure Anna Sonia Petronio, MD, FESC Head of Cardiac Catheterization Lab
More informationDurability of Pericardial Versus Porcine Aortic Valves
Journal of the American College of Cardiology Vol. 44, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.053
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationP have been used for mitral and aortic valve replacement
A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani,
More informationExtension to medium and low risk patients? Friedrich Eckstein University Hospital Basel
TAVI CON Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel Extension to medium and low risk patients? In octogenerians already reality in most of the swiss clinics!?
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationSurgery for Acquired Cardiovascular Disease
Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement W. R. E. Jamieson, MD, O. von Lipinski, MD, R. T.
More informationRead at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.
STRUCTURAL VALVE DETERIORATION IN MITRAL REPLACEMENT SURGERY: COMPARISON OF CARPENTIER-EDWARDS SUPRA-ANNULAR PORCINE AND PERIMOUNT PERICARDIAL BIOPROSTHESES W. R. Eric Jamieson, MD a Michel A. Marchand,
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationby Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D., L. H. Burr, M.D., R. T. Miyagishima, M.D.
Carpentier-Edwards Standard Porcine Bioprosthesis: Primary Tissue Failure (Structural Valve Deterioration) by Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D.,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationPr Fadi FARHAT Service de Chirurgie Cardiovasculaire Adulte et Transplantation Hôpital Louis Pradel, Bron, FRANCE. NOM Intitulé du topo Date.
5 ème Journée Scientifique de la Réunion de Concertation Pluridisciplinaire sur l Endocardite Infectieuse du CHU de Lyon ENDOCARDITE AIGUE INFECTIEUSE Y A-T-IL UN SUBSTITUT VALVULAIRE IDEAL? Pr Fadi FARHAT
More informationBioprostheses are prone to continuous degeneration
Twenty-Year Experience With the St. Jude Medical Biocor Bioprosthesis in the Aortic Position Walter B. Eichinger, MD, Ina M. Hettich, MD, Daniel J. Ruzicka, MD, Klaus Holper, MD, Carolin Schricker, Sabine
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationPrimary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: Hancock I Vekus Carpentier-Edwards at 4- to 7-Years Follow-up
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: A Hancock I Vekus Edwards at 4- to 7-Years Follow-up Francisco Nistal, M.D., Edurne Artifiano, M.D., and Ignacio Gallo,
More informationThe clinical experience reported in recent Western series has provided
Surgery for Acquired Cardiovascular Disease Yu et al Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease Hsi-Yu Yu, MD a Yi-Lwun Ho, MD b Shu-Hsun Chu, MD c Yih-Sharng
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationI will not discuss off label use or investigational use in my presentation.
I will not discuss off label use or investigational use in my presentation. Surgical valves Design and Durability Testing Potential Concerns Real Practice 1952-1962 1963-1966 1967-1969 1969-1977 1977-1984
More informationMitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients
Mitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients Kazutomo Minami, MD, Armin Zittermann, PhD, Sebastian Schulte-Eistrup, MD, Heinrich Koertke, MD, and Reiner
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationON-X and St.Jude Medical mechanical prosthesis. A paradox concept: they are equal but different
Accepted Manuscript ON-X and St.Jude Medical mechanical prosthesis. A paradox concept: they are equal but different Francesco Formica, MD, Stefano D Alessandro, MD, FECTS, Umberto Benedetto PII: S0022-5223(19)30709-3
More informationSotirios N. Prapas, M.D., Ph.D, F.E.C.T.S.
CORONARY ARTERY REVASCULARIZATION WITH MILD AORTIC STENOSIS: STRATEGIES OF TREATMENT 9 th ANNUAL MEETING OF THE EAB SOCIETY, Pravets, Bulgaria, 2012 Sotirios N. Prapas, M.D., Ph.D, F.E.C.T.S. Director
More information-The Living Aortic Valve- Repair or Else? Ismail El-Hamamsy, MD PhD
-The Living Aortic Valve- Repair or Else? Ismail El-Hamamsy, MD PhD Associate Professor Director, Aortic Surgery Division of Cardiac Surgery Montreal Heart Institute Université de Montreal PhD Thesis Imperial
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationNearly 40 years after the pioneering efforts of Starr and
Prognosis After Aortic Valve Replacement With a Bioprosthesis Predictions Based on Meta-Analysis and Microsimulation J.P.A. Puvimanasinghe, MBBS, MSc, MD; E.W. Steyerberg, PhD; J.J.M. Takkenberg, MD; M.J.C.
More informationThe CarboMedics bileaflet prosthetic heart was introduced
The CarboMedics Valve: Experience With 1,049 Implants José M. Bernal, MD, José M. Rabasa, MD, Francisco Gutierrez-Garcia, MD, Carlos Morales, MD, J. Francisco Nistal, MD, and José M. Revuelta, MD Department
More informationThe pulmonary valve is the most common heart valve
Biologic versus Mechanical Valve Replacement of the Pulmonary Valve After Multiple Reconstructions of the RVOT Tract S. Adil Husain, MD, and John Brown, MD Indiana University School of Medicine, Department
More informationThe CarboMedics prosthetic valve (Sulzer CarboMedics,
Long-Term Result of 1144 CarboMedics Mechanical Valve Implantations Chang Hyun Kang, MD, Hyuk Ahn, MD, Kyung Hwan Kim, MD, and Ki-Bong Kim, MD Department of Thoracic and Cardiovascular Surgery, Seoul National
More informationSurgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan
Surgical AF Ablation : Lesion Sets and Energy Sources What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Disclosures Consultant/Advisory Board: Abbott, Edwards Lifesciences
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationThe advantages and disadvantages of mechanical valve prostheses and
Surgery for Acquired Cardiovascular Disease Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients Ye-Ying Cen, MA Donald D. Glower, MD Kevin Landolfo,
More informationIschemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications
Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationIsolated Mitral Valve Replacement with the Hancock Bioprosthesis: A 13-Year Appraisal
Isolated Mitral Valve Replacement with the Hancock ioprosthesis: A 13-Year Appraisal Vincenzo Gallucci, M.D., berto ortolotti, M.D., Aldo Milano, M.D., Carlo Valfrk, M.D., Alessandro Mazzucco, M.D., and
More informationThe operative mortality associated with repeat heart valve surgery is. Repeat heart valve surgery: Risk factors for operative mortality
Surgery for Acquired Cardiovascular Disease Repeat heart valve surgery: Risk factors for operative mortality J. Mark Jones, MA, AFRCS a Hugh O Kane, MCh, FRCS a Dennis J. Gladstone, FRCS a Mazin A. I.
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationTreatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques
Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,
More informationAortic valve replacement: is porcine or bovine valve better?
Interactive CardioVascular and Thoracic Surgery Advance Access published December 4, 2012 Interactive CardioVascular and Thoracic Surgery (2012) 1 13 doi:10.1093/icvts/ivs447 BEST EVIDENCE TOPIC Aortic
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationRepeated mitral valve replacement in a patient with extensive annular calcification
CASE REPORT Open Access Repeated mitral valve replacement in a patient with extensive annular calcification Tadashi Kitamura 1,2*, Sachito Fukuda 1, Takahiro Sawada 1, Sumio Miura 1, Ikutaro Kigawa 1,3
More informationPorcine bioprosthesis use for surgical treatment of
Fifteen-Year Clinical Experience With the Biocor Porcine Bioprostheses in the Mitral Position Kaan Kırali, MD, Mustafa Güler, MD, Altuğ Tuncer, MD, Bahadır Dağlar, MD, Gökhan İpek, MD, Ömer Işık, MD, and
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript The mid-life crisis of the meta-analysis Joanna Chikwe, MD, FRCS, Aaron Weiss, MD PII: S0022-5223(18)33158-1 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.045 Reference: YMTC 13805 To
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationEstablishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa
More informationLONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS
LONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS David S. Peterseim, MD Ye-Ying Cen, MA Srinivas Cheruvu, MHS Kevin Landolfo, MD Thomas M. Bashore, MD James E.
More informationReoperations after primary aortic valve replacement
Third-Time Aortic Valve Replacement: Patient s and Operative Outcome Kasra Shaikhrezai, MD, MRCS, Giordano Tasca, MD, FETCS, Mohamed Amrani, PhD, FETCS, Gilles Dreyfus, MD, FETCS, and George Asimakopoulos,
More informationCHAPTER VIII AUTOGRAFT OR ALLOGRAFT AORTIC ROOT REPLACEMENT?
CHAPTER VIII AUTOGRAFT OR ALLOGRAFT AORTIC ROOT REPLACEMENT? Autograft or allograft aortic root replacement? Johanna J.M. Takkenberg, MD, Lex A. van Herwerden, MD, PhD, Ewout W. Steyerberg, PhD, Marinus
More informationControversy exists regarding which valve type is best
Treatment of Endocarditis With Valve Replacement: The Question of Tissue Versus Mechanical Prosthesis Marc R. Moon, MD, D. Craig Miller, MD, Kathleen A. Moore, BS, Phillip E. Oyer, MD, PhD, R. Scott Mitchell,
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationMitral Valve Surgery: Lessons from New York State
Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman & Program Director Department of Cardiovascular
More informationIn patients with prosthetic heart
CLINICIAN UPDATE Prosthetic Heart Valves and Pregnancy Lynne Hung, MD; Shahbudin H. Rahimtoola, MB, FRCP, MACP, MACC, DSc (Hon) In patients with prosthetic heart valves (PHV), pregnancy is associated with
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationP substitutes since the introduction of the Ionescu-
Mitroflow Pericardial Valve: Long-Term Durability Daniel Y. Loisance, MD, Jean-Philippe Mazzucotelli, MD, Patrick C. Bertrand, MD, Philippe H. Deleuze, MD, and Jean-Paul Cachera, MD Department of Surgical
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationAccepted Manuscript. Does valve choice matter in hemodialysis patients? Weiang Yan, MD, Rakesh C. Arora, MD, PhD, Michael H. Yamashita, MDCM, MPH
Accepted Manuscript Does valve choice matter in hemodialysis patients? Weiang Yan, MD, Rakesh C. Arora, MD, PhD, Michael H. Yamashita, MDCM, MPH PII: S0022-5223(18)32559-5 DOI: 10.1016/j.jtcvs.2018.09.055
More information25 different brand names >44 different models Sizes mm
Types of Prosthetic Valves BIOLOGIC STENTED Porcine xenograft Pericardial xenograft STENTLESS Porcine xenograft Pericardial xenograft Homograft (allograft) Autograft PERCUTANEOUS MECHANICAL Bileaflet Single
More informationCARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP
CARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP M. R. Aupart, MD P. H. Neville, MD S. Hammami, MD A. L. Sirineili, MD Y. A. Meurisse, MD M. A. Marchand, MD Objective: The
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationReoperation for isolated rheumatic tricuspid regurgitation
Moutakiallah et al. Journal of Cardiothoracic Surgery (2018) 13:104 https://doi.org/10.1186/s13019-018-0793-7 RESEARCH ARTICLE Reoperation for isolated rheumatic tricuspid regurgitation Open Access Younes
More informationEight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis
Eight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis Neal D. Kon, MD,* Robert D. Riley, MD, Sandy M. Adair, RN, Dalane W. Kitzman, MD, and A. Robert
More informationIndications and Late Results of Aortic Valve Repair
Indications and Late Results of Aortic Valve Repair Prof. Gebrine El Khoury Department of Cardiovascular and Thoracic Surgery Cliniques St. Luc Brussels, Belgium Aortic Valve Repair Question # 1 Can the
More informationQuality Outcomes Mitral Valve Repair
Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding
More information